vertex - Search News

Vertex Pharmaceuticals Shares Gain

MarketWatch · 24m

Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment.

The Wall Street Journal on MSN · 9h

Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug

Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug Administration approval.

Hosted on MSN · 9h

US FDA approves Vertex's non-opioid painkiller

The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator said on Thursday, offering a first-of-its-kind alternative to addictive opioid painkillers that have fueled a national crisis.

Vertex, NHS England

Vertex, U.K. reach reimbursement deal for CRISPR-based medicine for sickle cell disease

People in England with sickle cell will be able to get the world’s first CRISPR-based medicine under an agreement between the U.K. and Vertex.

Business Insider · 2h

Vertex In CASGEVY Reimbursement Deal With NHS England For Sickle Cell Disease Patients

Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel).

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

4don MSN

Is Vertex Pharmaceuticals Stock a Buy in 2025?

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results